TNF Pharmaceuticals, Inc. (NASDAQ:TNFA – Get Free Report) shares rose 1.9% on Tuesday . The company traded as high as $3.90 and last traded at $3.78. Approximately 268,258 shares changed hands during trading, a decline of 99% from the average daily volume of 32,220,806 shares. The stock had previously closed at $3.71.
TNF Pharmaceuticals Stock Down 2.1%
The firm has a market capitalization of $6.85 million, a price-to-earnings ratio of -0.02 and a beta of 2.04. The stock’s fifty day moving average is $3.87 and its two-hundred day moving average is $4.14.
About TNF Pharmaceuticals
TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases.
See Also
- Five stocks we like better than TNF Pharmaceuticals
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for TNF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TNF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
